The FDA designation expands Atossa’s investigational therapy into rare pediatric neuromuscular disease. ・The program could ...

As of Thursday, December 11, Atossa Therapeutics, Inc.’s ATOS share price has surged by 9.41%, which has investors ...

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.

Detailed price information for Atossa Therapeutics Inc (ATOS-Q) from The Globe and Mail including charting and trades.

Atossa Therapeutics (ATOS) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease, RPD, designation to ...

Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments ...

Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During ...

SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, ...

Atossa Therapeutics, Inc. announced the granting of a new patent (U.S. Patent No. 12,275,684) by the USPTO for its enteric oral formulations of (Z)-endoxifen, a potent Selective Estrogen Receptor ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the ...